ergoline and Deglutition-Disorders

ergoline has been researched along with Deglutition-Disorders* in 2 studies

Trials

1 trial(s) available for ergoline and Deglutition-Disorders

Article	Year
Cabergoline and silent aspiration in elderly patients with stroke. Journal of the American Geriatrics Society, 2003, Volume: 51, Issue:12 Topics: Aged; Cabergoline; Deglutition Disorders; Dopamine Agonists; Ergolines; Female; Humans; Male; Pneumonia, Aspiration; Stroke	2003

Other Studies

1 other study(ies) available for ergoline and Deglutition-Disorders

Article	Year
Experiences with a new ergoline (CF 25-397) in parkinsonism. Neurology, 1977, Volume: 27, Issue:12 Studies on rats with unilateral nigral lesions suggest that a new ergoline, CF 25-397, is a dopaminergic agonist that might improve parkinsonism. CF 25-397 induces less stereotyped behavior than other dopaminergic agents in rats, and might therefore cause less dyskinesia than levodopa in man. We investigated the clinical actions of CF 25-397 in nine patients. During treatment, severe deterioration resulted in hypokinesia and rigidity; five patients showed marked dysphagia and dysphonia. There was statistically significant deterioration in four timed tests. Mild improvement, not statistically significant, was noted in tremor. These results indicate that clinical implication of the response to potential therapeutic agents in rodent models of parkinsonism must be interpreted with caution. Topics: Aged; Animals; Corpus Striatum; Deglutition Disorders; Disease Models, Animal; Dopamine; Drug Evaluation; Drug Evaluation, Preclinical; Ergolines; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease; Rats; Species Specificity; Stereotyped Behavior; Tremor	1977

Article

Year

Experiences with a new ergoline (CF 25-397) in parkinsonism.

Neurology, 1977, Volume: 27, Issue:12

Studies on rats with unilateral nigral lesions suggest that a new ergoline, CF 25-397, is a dopaminergic agonist that might improve parkinsonism. CF 25-397 induces less stereotyped behavior than other dopaminergic agents in rats, and might therefore cause less dyskinesia than levodopa in man. We investigated the clinical actions of CF 25-397 in nine patients. During treatment, severe deterioration resulted in hypokinesia and rigidity; five patients showed marked dysphagia and dysphonia. There was statistically significant deterioration in four timed tests. Mild improvement, not statistically significant, was noted in tremor. These results indicate that clinical implication of the response to potential therapeutic agents in rodent models of parkinsonism must be interpreted with caution.

Topics: Aged; Animals; Corpus Striatum; Deglutition Disorders; Disease Models, Animal; Dopamine; Drug Evaluation; Drug Evaluation, Preclinical; Ergolines; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease; Rats; Species Specificity; Stereotyped Behavior; Tremor

1977